Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1695387 | 1.00 | MEN1 (0.42) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL3084586 | 0.77 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL7808059 | 0.77 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL7809339 | 0.77 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL7809336 | 0.77 | MEN1 (0.52) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL3227281 | 0.74 | MEN1 (0.48) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL28226467 | 0.74 | MEN1 (0.48) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL28900972 | 0.73 | MEN1 (0.42) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL399170 | 0.72 | TSHR (0.45) | MEN1KMT2ATSHRMAPK1THRB | |
| SCHEMBL3085848 | 0.71 | MEN1 (0.50) | MEN1KMT2ATSHRMAPK1THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | INSTITUT CURIE (FR) | 2021-11-02 | — | — | US | claimed |
| EP-3594343-B1 | USE OF A COMBINATION OF DBAIT MOLECULE AND PARP INHIBITORS TO TREAT CANCER | INST CURIE (FR) | 2021-04-21 | — | — | EP | claimed |
| US-20210023116-A1 | TREATMENT OF CANCER BY SYSTEMIC ADMINISTRATION OF DBAIT MOLECULES | VALERIO THERAPEUTICS (FR) | 2021-01-28 | — | — | US | claimed |
| EP-3325623-B3 | USE OF A COMBINATION OF DBAIT MOLECULE AND PARP INHIBITORS TO TREAT CANCER | INST CURIE (FR) | 2021-01-20 | — | — | EP | claimed |
| US-10821128-B2 | Treatment of cancer by systemic administration of Dbait molecules | ONXEO (FR) | 2020-11-03 | — | — | US | claimed |
| US-10563197-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | INSTITUT CURIE (FR) | 2020-02-18 | — | — | US | claimed |
| EP-3325623-B1 | USE OF A COMBINATION OF DBAIT MOLECULE AND PARP INHIBITORS TO TREAT CANCER | INST CURIE (FR) | 2019-06-05 | — | — | EP | claimed |
| US-20190091254-A1 | TREATMENT OF CANCER BY SYSTEMIC ADMINISTRATION OF DBAIT MOLECULES | VALERIO THERAPEUTICS (FR) | 2019-03-28 | — | — | US | claimed |
| EP-3423068-A1 | TREATMENT OF CANCER BY SYSTEMIC ADMINISTRATION OF DBAIT MOLECULES | ONXEO (FR) | 2019-01-09 | — | — | EP | claimed |
| US-20180362972-A1 | USE OF A COMBINATION OF DBAIT MOLECULE AND PARP INHIBITORS TO TREAT CANCER | VALERIO THERAPEUTICS (FR) | 2018-12-20 | — | — | US | claimed |
| WO-2018162439-A1 | NEW PREDICTIVE BIOMARKER FOR THE SENSITIVITY TO A TREATMENT OF CANCER WITH A DBAIT MOLECULE | ONXEO (FR) | 2018-09-13 | — | — | WO | claimed |
| EP-3325623-A1 | USE OF A COMBINATION OF DBAIT MOLECULE AND PARP INHIBITORS TO TREAT CANCER | Institut Curie (FR) | 2018-05-30 | — | — | EP | claimed |
| WO-2017186882-A1 | A METHOD OF PREDICTING A RESPONSE TO AN ANTI-TUMOR TREATMENT BY MEANS OF SIGNAL INTERFERING DNA MOLECULES | ONXEO (FR) | 2017-11-02 | — | — | WO | claimed |
| WO-2017013237-A1 | USE OF A COMBINATION OF DBAIT MOLECULE AND PARP INHIBITORS TO TREAT CANCER | INSTITUT CURIE (FR) | 2017-01-26 | — | — | WO | claimed |
| US-20230235327-A1 | A DBAIT MOLECULE IN COMBINATION WITH KRAS INHIBITOR FOR THE TREATMENT OF CANCER | VALERIO THERAPEUTICS (FR) | 2023-07-27 | — | — | US | disclosed |
| WO-2023111203-A1 | NEW CONJUGATED NUCLEIC ACID MOLECULES AND THEIR USES | ONXEO (FR) | 2023-06-22 | — | — | WO | disclosed |
| EP-4162045-A1 | A DBAIT MOLECULE IN COMBINATION WITH KRAS INHIBITOR FOR THE TREATMENT OF CANCER | ONXEO (FR) | 2023-04-12 | — | — | EP | disclosed |
| US-20130131155-A1 | Optimized In Vivo Delivery System with Endosomolytic Agents for Nucleic Acid Conjugates | DNA THERAPEUTICS (FR) | 2013-05-23 | — | — | US | disclosed |
| EP-2585113-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | DNA Therapeutics (FR) | 2013-05-01 | — | — | EP | disclosed |
| WO-2011161075-A1 | OPTIMIZED IN VIVO DELIVERY SYSTEM WITH ENDOSOMOLYTIC AGENTS FOR NUCLEIC ACID CONJUGATES | DNA THERAPEUTICS (FR) | 2011-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11162095-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | PARP10, PARP1, PARP3 | MEN1 2175/4885KMT2A 474/4885TSHR 4594/4885 |
| US-10821128-B2 | Treatment of cancer by systemic administration of Dbait molecules | CD2BP2, SDC1, BST2 | MEN1 787/4885KMT2A 3382/4885TSHR 3542/4885 |
| US-20210023116-A1 | TREATMENT OF CANCER BY SYSTEMIC ADMINISTRATION OF DBAIT MOLECULES | CD2BP2, SDC1, BST2 | MEN1 787/4885KMT2A 3382/4885TSHR 3542/4885 |
| US-20130131155-A1 | Optimized In Vivo Delivery System with Endosomolytic Agents for Nucleic Acid Conjugates | EEA1, RNASE1, ASGR1 | MEN1 708/4885KMT2A 2256/4885TSHR 2126/4885 |
| US-20190091254-A1 | TREATMENT OF CANCER BY SYSTEMIC ADMINISTRATION OF DBAIT MOLECULES | CD2BP2, SDC1, BST2 | MEN1 787/4885KMT2A 3382/4885TSHR 3542/4885 |
| US-10563197-B2 | Use of a combination of Dbait molecule and PARP inhibitors to treat cancer | PARP10, PARP1, PARP3 | MEN1 2175/4885KMT2A 474/4885TSHR 4594/4885 |
| US-20180362972-A1 | USE OF A COMBINATION OF DBAIT MOLECULE AND PARP INHIBITORS TO TREAT CANCER | PARP10, PARP1, PARP3 | MEN1 2175/4885KMT2A 474/4885TSHR 4594/4885 |
| US-20230235327-A1 | A DBAIT MOLECULE IN COMBINATION WITH KRAS INHIBITOR FOR THE TREATMENT OF CANCER | KRAS, TP53, NRAS | MEN1 768/4885KMT2A 1025/4885TSHR 4461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.